Host: The Japanese Society of Toxicology
Name : The 47th Annual Meeting of the Japanese Society of Toxicology
Date : 2020 -
Recent progress in cancer treatment significantly improved survival of patients with cancer. The novel targeted cancer therapies are associated with a wide spectrum of cardiovascular (CV) complications in patients. To understand CV toxicity screening and mechanisms of cardiotoxicities, it is necessary to establish a cardiotoxicity testing for anti-cancer agents. To date, we have developed a drug-induced proarrhythmia risk evaluation method using human iPS cell-derived cardiomyocytes (iPSC-CMs). We further extended iPSC-CMs to other types of cardiotoxicity evaluation, such as left ventricular dysfunction. Based on high-speed camera and a specific algorithm, we have developed a novel in vitro contractility assay system. Tyrosine kinase inhibitors reduced contractility speed using iPSC-CMs. We are currently planning to perform multi-site study for contractility and biomarkers, in collaboration with HESI cardiac safety committee. In the symposium, I would like to provide new insights on CV safety using iPSC-CMs during anti-cancer drug development.
